Drug maker Lupin on Tuesday said it has inked a strategic pact with Enzene Biosciences to launch biosimilar Cetuximab in India for treatment of head and neck cancer. Pune-based Enzene Biosciences, is the subsidiary of Alkem Laboratories.
Cetuximab is the first biosimilar developed for the intravenous infusion and has received approval from the Drug Controller General of India (DCGI) for its effectiveness in treating head and neck cancer, particularly Squamous Cell Carcinoma of the Head and Neck (SCCHN), making it a crucial solution for patients with recurrent locoregional or metastatic conditions.
Cetuximab is available as a 100mg vial.
In July 2009, the US Food and Drug Administration (USFDA) approved Eli Lilly and Merck’s Cetuximab (Erbitux) for treatment of metastatic colorectal cancer and head and neck cancer.
Head and neck cancer presents a significant public health challenge in India, with a staggering annual incidence of over 100,000 new cases. This malignancy affects critical regions of the head and neck, including the oral cavity, pharynx, larynx, and sinuses.The disease is often diagnosed at advanced stages, making effective treatment increasingly challenging. As a result, head and neck cancer carries a substantial burden, leading to significant difficulties in providing effective treatment and resulting in high mortality rates.“The launch of the first biosimilar Cetuximab reflects our steadfast dedication to improving access to solutions and enhancing patient outcomes,” said Rajeev Sibal, president – India Region Formulations.
